Concepedia

Paul Bycott

PB

Statistics

Publications

34

Citations

8.9K

H-Index

23

Active since

1996

Affiliations

Pfizer (United States)(Current)

Pfizer (Italy)

University of Chicago

Fox Chase Cancer Center

Moffitt Cancer Center

Paul Bycott is an author at Pfizer (United States) specializing in medicine, oncology, and cancer pharmacology.

Publications per year

1996–2016

34

Publications

34

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text

, , +14

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes et al. · Journal of Clinical Oncology · 2008 · 622 citations · Full text

, , +14

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson et al. · The Lancet Oncology · 2007 · 436 citations

, , +14

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Hedy L. Kindler, Tatsuya Ioka, D. J. Richel et al. · The Lancet Oncology · 2011 · 396 citations

, , +7

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

Jean‐Philippe Spano, Catherine Chodkiewicz, Joan Maurel et al. · The Lancet · 2008 · 249 citations

, , +8

1–5 of 34